Alnylam Pharmaceuticals (Nasdaq:ALNY) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

ALNY Stoklara Genel Bakış

Bir biyofarmasötik şirketi olan Alnylam Pharmaceuticals, Inc. ribonükleik asit girişimine dayalı yeni terapötikler keşfetmeye, geliştirmeye ve ticarileştirmeye odaklanmaktadır.

Şirket hakkında

ALNY temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	5/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 46.4% daha düşük bir oranda işlem görüyor

Kazançların yılda 65.21% oranında artması öngörülüyor

Kazançlar son 5 yılda yılda 8.9% oranında arttı

Risk Analizi

Negatif hissedar öz sermayesi

Hissedarlar geçen yıl sulandırıldı

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

Vutrisiran Poised To Transform Cardiomyopathy Treatment And Skyrocket Revenue Growth

US$285.91

5.7% undervalued

16.91%

Revenue growth p.a.

1 day ago

Alnylam Pharmaceuticals, Inc. Rakipler

BeiGene

NasdaqGS:BGNE

US$24.8b

Horizon Therapeutics

NasdaqGS:HZNP

US$26.6b

Natera

NasdaqGS:NTRA

US$16.2b

Seagen

NasdaqGS:SGEN

US$43.2b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Alnylam Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$269.53
52 Haftanın En Yüksek Seviyesi	US$287.55
52 Haftanın En Düşük Seviyesi	US$141.98
Beta	0.38
11 Aylık Değişim	6.21%
3 Aylık Değişim	7.37%
1 Yıllık Değişim	50.82%
33 Yıllık Değişim	32.83%
5 Yıllık Değişim	247.15%
Halka arzdan bu yana değişim	4,384.69%

Son Haberler & Güncellemeler

Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?

Sep 12

Alnylam: HELIOS-B Success Priced In Already

Aug 30

Recent updates

Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?

Sep 12

Alnylam: HELIOS-B Success Priced In Already

Aug 30

Analysts Are Upgrading Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its Latest Results

Aug 04

Broker Revenue Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher

Aug 02

RNAi: Winning In The Clinic, Now For The Market

Jun 25

Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation

Jun 03

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Mar 19

Is Alnylam's HELIOS-B Delay A Red Flag?

Mar 10

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Feb 18

Alnylam's Huge Opportunity

Jan 12

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues

Dec 18

Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares

Jun 23

Hissedar Getirileri

	ALNY	US Biotechs	US Pazar
7D	-1.8%	-0.2%	-0.4%
1Y	50.8%	22.1%	34.1%

Getiri vs. Endüstri: ALNY geçen yıl % 22.1 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: ALNY geçen yıl % 34.1 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is ALNY's price volatile compared to industry and market?
ALNY volatility
ALNY Average Weekly Movement	5.6%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: ALNY son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: ALNY 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2002	2,100	Yvonne Greenstreet	www.alnylam.com

Bir biyofarmasötik şirketi olan Alnylam Pharmaceuticals, Inc. ribonükleik asit girişimine dayalı yeni terapötikleri keşfetmeye, geliştirmeye ve ticarileştirmeye odaklanmaktadır. Pazarlanan ürünleri arasında yetişkinlerde kalıtsal transtiretin aracılı amiloidoz polinöropatisinin tedavisi için ONPATTRO (patisiran); yetişkinlerde polinöropatili hATTR amiloidozunun tedavisi için AMVUTTRA; akut hepatik porfirili yetişkinlerin tedavisi için GIVLAARI; ve primer hiperoksalüri tip 1 tedavisi için OXLUMO bulunmaktadır. Şirket ayrıca, transtiretin amiloidozu veya ATTR amiloidozu ile kardiyomiyopati tedavisi için patisiran; kompleman aracılı hastalıkları tedavi etmek için cemdisiran; alfa-1 karaciğer hastalığı tedavisi için Belcesiran; kronik HBV enfeksiyonu tedavisi için Elebsiran; hipertansiyon tedavisi için Zilebesiran; Alzheimer hastalığı ve serebral amiloid anjiyopati tedavisi için ALN-APP ve NASH tedavisi için ALN-HSD geliştirmektedir.

Alnylam Pharmaceuticals, Inc. Temel Bilgiler Özeti

Alnylam Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ALNY temel i̇stati̇sti̇kler
Piyasa değeri	US$34.86b
Kazançlar(TTM)	-US$72.94m
Gelir(TTM)	US$2.34b

14.8x

P/S Oranı

-474.4x

F/K Oranı

ALNY aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ALNY gelir tablosu (TTM)
Gelir	US$2.34b
Gelir Maliyeti	US$304.82m
Brüt Kâr	US$2.04b
Diğer Giderler	US$2.11b
Kazançlar	-US$72.94m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.57
Brüt Marj	87.00%
Net Kâr Marjı	-3.11%
Borç/Özkaynak Oranı	-79,140.2%

ALNY uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ALNY Stoklara Genel Bakış

Ödüller

Risk Analizi

Vutrisiran Poised To Transform Cardiomyopathy Treatment And Skyrocket Revenue Growth

Alnylam Pharmaceuticals, Inc. Rakipler

NasdaqGS:BGNE

US$24.8b

NasdaqGS:HZNP

US$26.6b

NasdaqGS:NTRA

US$16.2b

NasdaqGS:SGEN

US$43.2b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Alnylam Highlights New Data from Helios-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024

Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?

Alnylam: HELIOS-B Success Priced In Already

Alnylam Pharmaceuticals, Inc. Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

Price target increased by 8.3% to US$281

Consensus revenue estimates increase by 15%

Recent updates

Alnylam Highlights New Data from Helios-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024

Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?

Alnylam: HELIOS-B Success Priced In Already

Alnylam Pharmaceuticals, Inc. Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

Price target increased by 8.3% to US$281

Consensus revenue estimates increase by 15%

Analysts Are Upgrading Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its Latest Results

CEO & Director notifies of intention to sell stock

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Broker Revenue Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher

Alnylam Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2024

Alnylam Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

CEO & Director notifies of intention to sell stock

CEO & Director recently sold US$1.9m worth of stock

Independent Director notifies of intention to sell stock

Price target increased by 11% to US$243

RNAi: Winning In The Clinic, Now For The Market

Alnylam Pharmaceuticals, Inc. Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation

Key Executive notifies of intention to sell stock

Consensus estimates of losses per share improve by 13%

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.52 loss per share (vs US$1.40 loss in 1Q 2023)

Alnylam Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 02, 2024

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Alnylam Pharmaceuticals, Inc., Annual General Meeting, May 16, 2024

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Is Alnylam's HELIOS-B Delay A Red Flag?

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran Is Added to Standard of Care Antihypertensives

Co-Founder notifies of intention to sell stock

Consensus estimates of losses per share improve by 10%

CEO & Director recently sold US$1.0m worth of stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for Full Year Ending December 31, 2024

Alnylam Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Alnylam Pharmaceuticals, Inc. Announces Transition of Indrani L. Franchini as Executive Vice President, Chief Legal Officer and Secretary, Effective on March 1, 2024

Alnylam's Huge Opportunity

Forecast to breakeven in 2026

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues

Chief Innovation Officer notifies of intention to sell stock

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk

Consensus revenue estimates increase by 28%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alnylam Pharmaceuticals, Inc. Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine

Alnylam Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Alnylam Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

No longer forecast to breakeven

Marsha H. Fanucci Resigns from Board of Directors of Alnylam Pharmaceuticals, Inc

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

Consensus EPS estimates fall by 10%

Alnylam Pharmaceuticals, Inc. Announces Management Changes, Effective October 2, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Alnylam Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Alnylam Pharmaceuticals, Inc. Reports Updated Positive Interim Phase 1 Results for ALN-App, in Development for Alzheimer's Disease and Cerebral Amyloid Angiopathy

Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares

Alnylam Pharmaceuticals, Inc. Presents 18-Month Results from the Apollo-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year of 2023